Movement Alert｜Vaxcyte, Inc. Intraday Rise 53.91%, Pneumonia Vaccine Meets Phase 3 Trial Endpoints

Market Focus

Oct 05

On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met all primary immunogenicity endpoints compared to Prevnar 20 and Capvaxive in a Phase 3 trial testing efficacy against invasive pneumococcal disease and pneumonia. VAX-31 demonstrated favorable safety profiles across all age groups studied.

These trial results will form the basis for planned biologics license application submissions to the FDA in the first half of 2028. The company expects to report results from two additional adult Phase 3 trials in the first half of 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112971972"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112971972\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112971972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-05 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112971972","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Vaxcyte, Inc. Intraday Rise 53.91%, Pneumonia Vaccine Meets Phase 3 Trial Endpoints","media":"Market Focus","content":"<p><p>On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met all primary immunogenicity endpoints compared to Prevnar 20 and Capvaxive in a Phase 3 trial testing efficacy against invasive pneumococcal disease and pneumonia. VAX-31 demonstrated favorable safety profiles across all age groups studied.</p><p>These trial results will form the basis for planned biologics license application submissions to the FDA in the first half of 2028. The company expects to report results from two additional adult Phase 3 trials in the first half of 2027.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Vaxcyte, Inc. Intraday Rise 53.91%, Pneumonia Vaccine Meets Phase 3 Trial Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Vaxcyte, Inc. Intraday Rise 53.91%, Pneumonia Vaccine Meets Phase 3 Trial Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-05 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met all primary immunogenicity endpoints compared to Prevnar 20 and Capvaxive in a Phase 3 trial testing efficacy against invasive pneumococcal disease and pneumonia. VAX-31 demonstrated favorable safety profiles across all age groups studied.</p><p>These trial results will form the basis for planned biologics license application submissions to the FDA in the first half of 2028. The company expects to report results from two additional adult Phase 3 trials in the first half of 2027.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCVX","symbol_name":"Vaxcyte, Inc.","start_time":0,"source_url":"","article_id":"1112971972","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112971972","pubTimestamp":1791207923,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCVX":"Vaxcyte, Inc."},"translate_title":"动向提醒|Vaxcyte, Inc.盘中大涨53.91%，肺炎疫苗达到3期试验终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1},"content_text":"On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met all primary immunogenicity endpoints compared to Prevnar 20 and Capvaxive in a Phase 3 trial testing efficacy against invasive pneumococcal disease and pneumonia. VAX-31 demonstrated favorable safety profiles across all age groups studied.These trial results will form the basis for planned biologics license application submissions to the FDA in the first half of 2028. The company expects to report results from two additional adult Phase 3 trials in the first half of 2027.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}